IDEAS home Printed from https://ideas.repec.org/a/sae/medema/v14y1994i2p108-117.html
   My bibliography  Save this article

Cost - Effectiueness of Streptokinase for Acute Myocardial Infarction

Author

Listed:
  • Andre S. Midgette
  • John B. Wong
  • Joni R. Beshansky
  • Avi Porath
  • Craig Fleming
  • Stephen G. Pauker

Abstract

Objective: To determine the effects of infarct location and of the likelihood of infarction on the cost-effectiveness of intravenous streptokinase (IVSK) for suspected acute myocardial infarction (AMI). Design: A meta-analysis of short-term survival was combined with a simple decision tree to determine marginal cost-effectiveness ratios for different infarct locations and different likelihoods of AMI (pMI). Setting: Six randomized trials comparing IVSK with conservative treatment. Patients: 31,940 patients with onset of symptoms of AMI from four to 24 hours earlier and, with the exception of one trial, electrocardiographic abnormalities. Patients with contraindications to thrombolytic treatment such as uncontrolled hypertension were excluded. Main results: If AMI is certain, treatment with IVSK has marginal cost- effectiveness ratios for each additional life saved of $9,900, $56,600, and $28,400, respec tively, for patients with anterior, inferior, and other locations of AMI. If pMI is 50%, treatment with IVSK has marginal cost-effectiveness ratios for each additional life saved of $22,700, $131,800, and $63,100, respectively, for patients with anterior, inferior, and other locations of AMI. Conclusions: The marginal cost-effectiveness ratio for IVSK therapy of inferior infarction is six times that for anterior infarction and rises steeply as the presence of AMI becomes less certain. Assuming society is willing to pay $250,000 per life saved, IVSK therapy should be given if the chance of acute anterior infarction exceeds 7%, if the chance of inferior infarction exceeds 32%, or if the chance of infarction in other locations exceeds 17%. In patients with suspected acute myocardial infarction, IVSK saves lives and is a reasonable use of societal resources. Key words: thrombolytic therapy; acute myocardial infarction; cost-effectiveness. (Med Decis Making 1994;14:108-117)

Suggested Citation

  • Andre S. Midgette & John B. Wong & Joni R. Beshansky & Avi Porath & Craig Fleming & Stephen G. Pauker, 1994. "Cost - Effectiueness of Streptokinase for Acute Myocardial Infarction," Medical Decision Making, , vol. 14(2), pages 108-117, April.
    • Handle: RePEc:sae:medema:v:14:y:1994:i:2:p:108-117
    DOI: 10.1177/0272989X9401400203
    as

    Download full text from publisher

    File URL: https://journals.sagepub.com/doi/10.1177/0272989X9401400203
    Download Restriction: no
    File URL: https://libkey.io/10.1177/0272989X9401400203?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:sae:medema:v:14:y:1994:i:2:p:108-117. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: SAGE Publications (email available below). General contact details of provider: .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.